Edgestream Partners L.P. Acquires 294,696 Shares of Pfizer Inc. (NYSE:PFE)

Edgestream Partners L.P. increased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 612.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 342,794 shares of the biopharmaceutical company's stock after purchasing an additional 294,696 shares during the period. Edgestream Partners L.P.'s holdings in Pfizer were worth $8,686,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of PFE. Brighton Jones LLC boosted its stake in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC boosted its stake in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after buying an additional 2,087 shares during the period. Madison Investment Advisors LLC purchased a new position in Pfizer during the fourth quarter worth $5,360,000. one8zero8 LLC purchased a new position in Pfizer during the fourth quarter worth $1,656,000. Finally, Envestnet Portfolio Solutions Inc. boosted its stake in Pfizer by 3.6% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 600,366 shares of the biopharmaceutical company's stock worth $15,928,000 after buying an additional 20,991 shares during the period. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have commented on PFE. TD Cowen dropped their price objective on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research note on Tuesday, April 22nd. Citigroup boosted their target price on shares of Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Jefferies Financial Group boosted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. BMO Capital Markets lowered their target price on shares of Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Finally, Bank of America boosted their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Pfizer presently has an average rating of "Hold" and a consensus target price of $28.55.

Pfizer Trading Down 0.5%

Shares of NYSE:PFE opened at $25.65 on Monday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The firm has a market capitalization of $145.83 billion, a price-to-earnings ratio of 18.59, a price-to-earnings-growth ratio of 0.93 and a beta of 0.58. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The business's 50 day moving average price is $23.89 and its 200-day moving average price is $24.78.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the prior year, the company earned $0.82 EPS. The firm's revenue was down 7.8% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.71%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.